Literature DB >> 6215070

Quantitative analysis of 5-fluorouracil and 5,6-dihydrofluorouracil in plasma by gas chromatography mass spectrometry.

C Aubert, J P Sommadossi, P Coassolo, J P Cano, J P Rigault.   

Abstract

5-Fluorouracil and 5,6-dihydro-5-fluorouracil were analysed in the plasma of patients by combined gas chromatography mass spectrometry. 5-Bromouracil was the internal standard. After extraction from plasma with an isopropanol-diethyl ether mixture (20/80) the components were pentylated and the derivatives produced extracted into diethyl ether. Electron impact mass spectrometry was used for the simultaneous quantitative determinations of 5-fluorouracil and 5,6-dihydro-5-fluorouracil (detection limit 10 ng ml-1 5-fluorouracil, 80 ng ml-1 5,6-dihydro-5-fluorouracil). Chemical ionization was utilized to measure 5,6-dihydro-5-fluorouracil concentrations less than 80 ng ml-1 (sensitivity 10 ng ml-1). The biological applicability of these two techniques was demonstrated by analysing plasma samples from patients after administration of 5-fluorouracil or 5'-deoxyfluorouridine by intravenous injections and infusions.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6215070     DOI: 10.1002/bms.1200090806

Source DB:  PubMed          Journal:  Biomed Mass Spectrom        ISSN: 0306-042X


  4 in total

1.  New approach to metabolism of 5'-deoxy-5-fluorouridine in humans with fluorine-19 NMR.

Authors:  M C Malet-Martino; R Martino; A Lopez; J P Béteille; M Bon; J Bernadou; J P Armand
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

2.  Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients.

Authors:  L J Schaaf; B R Dobbs; I R Edwards; D G Perrier
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 3.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

4.  Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2'-deoxyuridine.

Authors:  F M Muggia; K K Chan; C Russell; N Colombo; J L Speyer; K Sehgal; S Jeffers; J Sorich; L Leichman; U Beller
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.